Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. VANI
VANI logo

VANI

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

VANI News

Vivani Medical Partners with Novo Nordisk for Semaglutide Implant Evaluation

1d agoNASDAQ.COM

Vivani Medical Partners with Novo Nordisk to Evaluate NanoPortal Implant for Semaglutide

1d agoseekingalpha

Vivani Signs New Agreement with Novo Nordisk for NPM-139 Evaluation

1d agoNewsfilter

ClearOne's Strategic Shift and Merger with Cortigent

5d agostocktwits

Vivani Medical Appoints August Moretti to Board of Directors

Jun 26 2026Newsfilter

Vivani Receives Approval for SLIM-1 Clinical Trial in Australia

Jun 25 2026Newsfilter

Vivani Medical Reports Q1 Results with EPS of -$0.08

May 13 2026seekingalpha

Vivani Medical Reports FY GAAP EPS Miss

Mar 26 2026seekingalpha

Vivani Medical Completes First-in-Human Study for Semaglutide Implant

Mar 26 2026Newsfilter

Cortigent's Brain Implant Device Receives FDA Approval

Jan 29 2026Newsfilter

Vivani Medical Prices $4.5M Offering for Growth Initiatives

Jan 26 2026seekingalpha

Vivani Medical Launches Stock Offering to Raise $4.5 Million

Jan 26 2026NASDAQ.COM

Vivani Medical's Cortigent Unveils Orion Visual Prosthesis Insights at NANS 2026

Jan 23 2026NASDAQ.COM

Cortigent's Orion Visual Stimulation System Completes 6-Year Feasibility Study

Jan 22 2026Newsfilter

Vivani Medical Shares Business Update and Announces Financial Results for Third Quarter 2025

Nov 13 2025Newsfilter

GNTA, BBIO, AMRN Surge in After-Hours Trading: Major Biotech Factors Fueling Stock Increases

Oct 29 2025NASDAQ.COM